Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 4 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Tristan Manalac, Yesterday
Hormone treatment confers beneficial mood effects in postmenopausal women, according to a recent study, which reports that a transdermal oestradiol plus intermittent micronized progesterone (TE+IMP) treatment regimen is more effective than placebo at reducing depressive symptoms in peri- and postmenopausal women.

Vascular involvement in MLKI lowers knee function

30 Sep 2017

Knee function is lower in multiligament knee injury (MLKI) patients with artery injury requiring bypass grafts compared with MLKI patients without vascular involvement, a new matched-cohort analysis finds.

The retrospective study included 16 MLKI patients with vascular injury that required bypass grafting (mean age 30.3 years) and a matched cohort of 32 MLKI patients without vascular involvement (mean age 31.4 years).

In terms of knee function, the mean Lysholm scores for the vascular injury and control cohorts were 62.5 (16 to 100) and 86.4 (51 to 100) points, respectively, with the difference reaching statistical significance (p=0.001).

Controls also scored significantly higher on the International Knee Documentation Committee (IKDC) scale with a mean score of 83.8 (35.6 to 100) points compared to the 59.7 (14.9 to 100) points of the vascular injury patients (p=0.002).

Excellent ratings in the IKDC and Lysholm scales were recorded for only 19 and 25 percent of the vascular cohort, respectively. This was notably lower than the 66 and 69 percent in the control cohort, respectively.

There were no significant differences between the two groups in terms of extension (p=0.7) and flexion (p=0.6) ranges of motion, knee stability, time to surgery (p=0.7), knee dislocation grade (p=1.0), and percentage with peroneal nerve injury (p=1.0).

While body mass index (BMI; p=0.53) was also similar between the two groups, a BMI of more than 30 kg/m2 was found to be a significant predictor for lower Lysholm (p=0.0008) and IKDC (p=0.0009) scores.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 4 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Tristan Manalac, Yesterday
Hormone treatment confers beneficial mood effects in postmenopausal women, according to a recent study, which reports that a transdermal oestradiol plus intermittent micronized progesterone (TE+IMP) treatment regimen is more effective than placebo at reducing depressive symptoms in peri- and postmenopausal women.